Asthma for kids

Article source Link, Article source Link,

In the United States, turnover fell 13% to 2.1 billion, due to generic competition to mature brands. European sales grew 6% to 1.6 billion, emerging markets sales rose 9% to 581 million and Asia Pacific/Japan sales improved 5% to 464 million from the third quarter of 2007.
On a constant exchange rate, GSK's total sales from respiratory products increased 3% to 1.35 billion. Total sales of Seretide/Advair, for asthma and COPD, were up 7% to 982 million, with U.S. sales improving 5% to 515 million.
Total sales from anti-virals was 792 million, up 1% from last year, with the U.S

U.S. prescriptions for SINGULAIR, that is total prescriptions, were down approximately 8% in the third quarter versus third quarter '07. Similar to the decline in the overall respiratory market. The combined allergy and asthma market without Zyrtec, which was down approximately 6%.
As I have mentioned in previous quarters, the U.S. performance for SINGULAIR continued to be effected by the switch of Zyrtec OTC, the weak spring allergy season, and the FDA early communication, this spring.
We are determined to improve the performance of SINGULAIR in the U.S. in the fourth quarter and we have significant resources and plans underway to grow SINGULAIR during the fall allergy season and the end of year asthma season

Blog Archives:
Treating asthma

Aprilia mopeds

Toddler polo shirt

Tile bathroom walls

Floor tile installation

Political tee shirts

Buying mopeds

Womens denim shirt

Razz moped

Dog tee shirt

Toilet cabinet